ClinicalTrials.Veeva

Menu
F

ForCare Clinical Research | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Baricitinib
JNJ-77242113
LY3009104
Upadacitinib
PF-04965842
Ruxolitinib
Guselkumab
Lebrikizumab
PF-06651600
LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

29 of 127 total trials

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (Tranquillo LTE)

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-...

Active, not recruiting
COVID-19
Biological: CVXGA (CVXGA50)
Biological: COMIRNATY®

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still bei...

Begins enrollment in 3 months
Overweight
Obesity
Drug: Placebo CagriSema
Drug: Cagrisema

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. A...

Enrolling
Alopecia Areata
Drug: Placebo - 50 mg
Drug: Ritlecitinib 50 mg

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Active, not recruiting
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Active, not recruiting
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Active, not recruiting
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: ONO-2020

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting
Plaque Psoriasis
Drug: Ustekinumab
Drug: Matching Placebo to Ustekinumab

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Placebo to match NAV-240
Drug: NAV-240

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Invitation-only
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

Trial sponsors

Lilly logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Incyte logo
Boehringer Ingelheim logo
Amgen logo
Haisco Pharmaceutical Group logo
I
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems